Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

NCT01624142 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Familial Hypercholesterolemia

Interventions

BIOLOGICAL: Evolocumab

Sponsor

Amgen